Under our Pharmorphix® offering, we have a proven track record of delivering excellence for customers in early drug development. By applying our world-leading understanding of solid form science, we can improve the properties and success rates of drug candidates for the pharmaceutical industry.
We are a trusted and experienced partner, having completed over 2,000 customer projects on a wide range of structurally diverse and complex APIs. Our scientists have a unique understanding of how best to support customers to progress their compounds through the drug development process.
Our state-of-the-art facility based in Cambridge, U.K., offers one of the most comprehensive arrays of integrated solid form, pre-formulation, particle engineering and chemical development capabilities available to the pharmaceutical and biotechnology industries. We have the flexibility and breadth of expertise to adapt to your project’s evolving needs.
Long-term partnership
Our success in solid form sciences is built on strong partnership and collaboration.
We work closely with our customers to fully understand their solid form and particle engineering needs; providing the right recommendation at an early stage: our unbiased approach to technology selection means we have the knowledge and expertise to be able to select the right technology using as small amounts of material as possible.
We’re delighted to have achieved an average Net Promoter Score (NPS) of 82% over the past four years up to September 2025.
Collaborate with Veranova
“We had a fruitful collaboration with Olana, Carrie and the expert team at Veranova. Their work proved decisively that non-systemic kinase inhibitors could be formulated in solution for topical ocular delivery and altered the course of our ophthalmology candidate selection dramatically. The team then formulated the development candidate in a clinically-acceptable vehicle that successfully demonstrated proof-of-concept in Phase 2a trials. The robustness of this formulation was then also confirmed through top-notch stability studies that included the careful analysis of degradation products. In summary, our collaboration was highly successful, and I wholeheartedly recommend working with Olana and the Veranova team!”
– Matthew Fyfe, Head of Chemistry and IP, Topivert
“The Veranova Cambridge team has proven yet again to be a terrific partner in our product development work. They conducted characterization studies, including limit of detection and x-ray powder diffraction (XRPD) analysis, to support a regulatory filing. Veranova executed the work to a high standard and also provided valuable problem solving when alternative testing ideas were needed. The final report was very comprehensive and included useful interpretation. Throughout all phases of the work, Veranova’s project management and communication were excellent.”
– Kyle Kleinbeck, Senior Scientist, CMC, Center for Biomedical Research at the Population Council
Our comprehensive and industry-leading range of technologies, together with our extensive experience in handling highly potent APIs and IP creation through particle science, give you the best results with confidence.
We commit to building strong relationships through experienced advisers that understand the industry; utilizing our unparalleled ability to work on small quantities from an early stage throughout your process.
We were honored to welcome Nobel Prize laureate, Professor of Chemistry at Stanford University, and Veranova Advisory Board member, Carolyn Bertozzi to our SCALE 2025 Symposium event in July.
Listen to Carolyn’s talk where she discusses her decades-long work developing bioorthogonal and click chemistries, and how these innovations are enabling the construction of complex therapeutic modalities across pharma today.
Read our latest white paper highlighting critical analytical techniques necessary for the characterization of ADCs, emphasizing their physicochemical properties, biological activity, stability assessments, and regulatory implications.
In recent years, interest in psychedelics for therapeutic use has increased. Among these is psilocybin, the world’s most studied psychedelic compound for the treatment of mental health conditions. This Expert Insight explores the potential of this molecule, and the challenges associated with synthesizing it at scale.
Discover new ways to advance your science with Veranova.
Contact us